Efficacy and Safety of Risperidone in the Treatment of Schizoaffective Disorder: Initial Results From a Large, Multicenter Surveillance Study
J Clin Psychiatry 2001;62(8):623-630
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: An adequate therapy for psychotic
disorders needs to be effective against mood as well as psychotic
symptoms. Analyses of data from clinical trials of risperidone in
schizophrenia and small open-label studies in mania suggest that
risperidone may have this broad efficacy profile. We present data
on a 6-week trial of risperidone for the treatment of
schizoaffective disorder that was part of a larger, 6-month
surveillance study of patients with affective disorders.
Method: One hundred two patients suffering from
schizoaffective disorder (DSM-IV or ICD-10) entered the trial.
Inclusion criteria consisted of a current DSM-IV diagnosis of
schizoaffective disorder, bipolar type; DSM-IV manic or mixed
psychotic episode; and a Young Mania Rating Scale (YMRS) score
> 7 for a mixed episode (> 20 for a manic episode).
Assessments included the YMRS, the Positive and Negative Syndrome
Scale (PANSS), the Hamilton Rating Scale for Depression (HAM-D),
the 4-item Clinical Global Impressions (CGI) scale, and the UKU
Side Effect Rating Scale subscale for neurologic side effects.
For patients entering the study, open-label risperidone therapy
was added to their existing regimens of mood-stabilizing
treatments. Other antipsychotic drugs were not allowed.
Results: Ninety-five patients completed the
6-week trial. At week 6, the mean ± SD dose of risperidone was
4.7 ± 2.5 mg/day. The mean scores on the assessment scales at
baseline and week 6 (unless otherwise stated) were as follows:
YMRS, 22.7 and 4.7, an improvement of 18.0 points (p < .0001);
PANSS (at baseline and week 4), 74.1 and 54.2, an improvement of
19.9 points (p < .0001); HAM-D, 14.0 and 7.4, an improvement
of 6.6 points (p < .0001); CGI (at baseline and week 4), 2.6
and 1.7, an improvement of 0.9 points (p < .0001). At week 4,
most patients had shown improvement in symptom severity, and 9.3%
were completely symptom-free. There were no statistically
significant differences between baseline and week 4 in the
severity of extrapyramidal symptoms as measured by the UKU.
Risperidone was well tolerated; side effects were few and
Conclusion: The results to date with risperidone indicate that it may have both antipsychotic and mood-stabilizing properties. Despite the limitations of the open-label design, the results indicate that risperidone is a safe and effective therapy in combination with mood-stabilizers for the treatment of patients with manic, hypomanic, and depressive symptoms of mixed episodes in schizoaffective disorder, bipolar type.